PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 193.50 thousand shares for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2022-11-03
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-09-30 was 193.50K shares, a 9.94% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-06-30 was 284.25K shares, a 52.35% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-03-31 was 1.74M shares, a 31.71% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2021-12-31 was 207.00K shares, a 14.81% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2021 was 3.53M shares, a 67.40% increase from fiscal 2020.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2020 was 2.11M shares, a 60.26% increase from fiscal 2019.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2019 was 1.32M shares, a 68.22% decline from fiscal 2018.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2018 was 4.14M shares, a 164.28% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2022-09-30 | 193.50K shares 10-Q · filed 2022-11-03 | 477.75K shares derived: sum of 2 quarters · filed 2022-11-03 | 2.22M shares 10-Q · filed 2022-11-03 | 2.43M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 284.25K shares 10-Q · filed 2022-08-08 | 2.03M shares 10-Q · filed 2022-08-08 | 2.23M shares derived: sum of 3 quarters · filed 2022-08-08 | 2.41M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-03-31 | 1.74M shares 10-Q · filed 2022-05-05 | 1.95M shares derived: sum of 2 quarters · filed 2022-05-05 | 2.12M shares derived: sum of 3 quarters · filed 2022-11-03 | 2.72M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-12-31 | 207.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 383.00K shares derived: sum of 2 quarters · filed 2022-11-03 | 979.50K shares derived: sum of 3 quarters · filed 2022-11-03 | 3.53M shares 10-K · filed 2022-02-25 |
| 2021-09-30 | 176.00K shares 10-Q · filed 2022-11-03 | 772.50K shares derived: sum of 2 quarters · filed 2022-11-03 | 3.32M shares 10-Q · filed 2022-11-03 | 3.57M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | 596.50K shares 10-Q · filed 2022-08-08 | 3.15M shares 10-Q · filed 2022-08-08 | 3.39M shares derived: sum of 3 quarters · filed 2022-08-08 | 3.54M shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | 2.55M shares 10-Q · filed 2022-05-05 | 2.79M shares derived: sum of 2 quarters · filed 2022-05-05 | 2.94M shares derived: sum of 3 quarters · filed 2022-05-05 | 3.20M shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | 243.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 390.00K shares derived: sum of 2 quarters · filed 2022-02-25 | 653.50K shares derived: sum of 3 quarters · filed 2022-02-25 | 2.11M shares 10-K · filed 2022-02-25 |
| 2020-09-30 | 147.00K shares 10-Q · filed 2021-11-04 | 410.50K shares derived: sum of 2 quarters · filed 2021-11-04 | 1.87M shares 10-Q · filed 2021-11-04 | 1.89M shares derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | 263.50K shares 10-Q · filed 2021-08-05 | 1.72M shares 10-Q · filed 2021-08-05 | 1.74M shares derived: sum of 3 quarters · filed 2022-02-25 | 2.04M shares derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | 1.46M shares 10-Q · filed 2021-05-11 | 1.48M shares derived: sum of 2 quarters · filed 2022-02-25 | 1.77M shares derived: sum of 3 quarters · filed 2022-02-25 | 1.92M shares derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | 25.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 318.00K shares derived: sum of 2 quarters · filed 2022-02-25 | 463.00K shares derived: sum of 3 quarters · filed 2022-02-25 | 1.32M shares 10-K · filed 2022-02-25 |
| 2019-09-30 | 292.50K shares 10-Q · filed 2020-11-04 | 437.50K shares derived: sum of 2 quarters · filed 2020-11-04 | 1.29M shares 10-Q · filed 2020-11-04 | 1.38M shares derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | 145.00K shares 10-Q · filed 2020-08-06 | 997.98K shares 10-Q · filed 2020-08-06 | 1.09M shares derived: sum of 3 quarters · filed 2020-08-06 | 1.09M shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | 852.98K shares 10-Q · filed 2020-05-06 | 947.48K shares derived: sum of 2 quarters · filed 2020-05-06 | 947.48K shares derived: sum of 3 quarters · filed 2020-05-06 | 3.90M shares derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | 94.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | 94.50K shares derived: sum of 2 quarters · filed 2020-03-03 | 3.05M shares derived: sum of 3 quarters · filed 2020-03-03 | 4.14M shares 10-K · filed 2020-03-03 |
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-05 | 2.95M shares derived: sum of 2 quarters · filed 2019-11-05 | 4.05M shares 10-Q · filed 2019-11-05 | 4.17M shares derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | 2.95M shares 10-Q · filed 2019-08-06 | 4.05M shares 10-Q · filed 2019-08-06 | 4.17M shares derived: sum of 3 quarters · filed 2020-03-03 | 4.33M shares derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | 1.09M shares 10-Q · filed 2019-05-07 | 1.21M shares derived: sum of 2 quarters · filed 2020-03-03 | 1.38M shares derived: sum of 3 quarters · filed 2020-03-03 | 1.81M shares derived: sum of 4 quarters · filed 2020-03-03 |
| 2017-12-31 | 119.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | 282.00K shares derived: sum of 2 quarters · filed 2020-03-03 | 712.00K shares derived: sum of 3 quarters · filed 2020-03-03 | 1.57M shares 10-K · filed 2020-03-03 |
| 2017-09-30 | 162.50K shares 10-Q · filed 2018-11-06 | 592.50K shares derived: sum of 2 quarters · filed 2018-11-06 | 1.45M shares 10-Q · filed 2018-11-06 | |
| 2017-06-30 | 430.00K shares 10-Q · filed 2018-08-07 | 1.28M shares 10-Q · filed 2018-08-07 | ||
| 2016-12-31 | 1.51M shares 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |